Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study

Dufour, Patrick; Lang, J. M.; Giron, C; Duclos, Bernard; Haehnel, P; Jaeck, Daniel; Jin-Hyang, Jung; Oberling, F.

doi:10.1007/bf01877380

Cited by 76 publications

(51 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significantly, a phase II clinical trial performed almost two decades ago demonstrated an increased survival rate of patients with breast cancer who received chemotherapy plus an active disulfiram metabolite compared with chemotherapy alone (40). Altogether, these observations suggest a potential benefit of ALDH inhibition for the treatment of breast and other cancers.…”

Section: Rosmentioning

confidence: 68%

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

et al. 2014

View full text Add to dashboard Cite

Selective kinase inhibitors have emerged as an important class of cancer therapeutics, and several such drugs are now routinely used to treat advanced-stage disease. However, their clinical benefit is typically short-lived because of the relatively rapid acquisition of drug resistance following treatment response. Accumulating preclinical and clinical data point to a role for a heterogeneous response to treatment within a subpopulation of tumor cells that are intrinsically drug-resistant, such as cancer stem cells. We have previously described an epigenetically determined reversibly drug-tolerant subpopulation of cancer cells that share some properties with cancer stem cells. Here, we define a requirement for the previously established cancer stem cell marker ALDH (aldehyde dehydrogenase) in the maintenance of this drug-tolerant subpopulation. We find that ALDH protects the drug-tolerant subpopulation from the potentially toxic effects of elevated levels of reactive oxygen species (ROS) in these cells, and pharmacologic disruption of ALDH activity leads to accumulation of ROS to toxic levels, consequent DNA damage, and apoptosis specifically within the drug-tolerant subpopulation. Combining ALDH inhibition with other kinase-directed treatments delayed treatment relapse in vitro and in vivo, revealing a novel combination treatment strategy for cancers that might otherwise rapidly relapse following single-agent therapy. Cancer Res; 74(13); 3579-90. Ó2014 AACR.

show abstract

Section: Rosmentioning

confidence: 68%

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…DSF has also been shown to potentiate the cytotoxic effect of anticancer drugs while protecting normal cells (Dufour et al, 1993;Verma et al, 1990). The clinical use of DSF as an anti-cancer drug is limited by its poor oral bioavailability and rapid metabolism in vivo (Agarwal et al, 1983).…”

Section: Introductionmentioning

confidence: 98%

Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram

Ramadhani

Shabir

McConville

2014

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Some dithiocarbamates have also been found to be pharmacologically active, used for the treatment of alcoholism (Jacobsen 1950), and tested in clinical trials for various infections including HIV (Hersh et al 1991;Kaplan et al 1989;Lang et al 1988) and cancers (Dufour et al 1993; Francis et al 1993;Verma et al 1990). The antitumor effects of these dithiocarbamates can in part be attributed to their ability to complex tumor cellular copper, leading to binding to and inhibition of the proteasome and in turn initiating tumor cell-specific apoptosis (Buac et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Characterization, and Antitumor Activity of New Organotin(IV) Methoxyethyldithiocarbamate Complexes

Awang¹,

FarahanaKamaludin²,

Baba

et al. 2016

Orient. J. Chem

View full text Add to dashboard Cite

Two new organotin(IV) dithiocarbamate complexes of the type R 3 SnL and R 2 SnL 2 (L = methoxyethyldithiocarbamate and R = C 6 H 5 or C 4 H 9 ) were synthesized in good yields. The organotin complexes were suitably characterized by elemental analysis, FT-IR, 1 H, and 13 C NMR spectroscopies. These complexes were prepared in situ. Elemental analysis data (carbon, hydrogen, nitrogen, and sulfur) showed an agreement with the suggested formula structures. The infrared spectra of these complexes showed three important peaks for n(C=N), n(C=S), and n(Sn-S) in the region of 1450-1463, 992-994, and 324-326 cm -1 respectively. Data for 13 C NMR spectroscopy showed an important peak in the region of d C 197-201 ppm that corresponded to the NCS 2 group. These complexes were evaluated for their in vitro anti proliferative activities against HL-60 cell lines. The results showed that both of these complexes had high cytotoxicities toward HL-60 cell lines with the IC 50 values below 1 mM.

show abstract

Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study

Cited by 76 publications

References 14 publications

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram

Synthesis, Characterization, and Antitumor Activity of New Organotin(IV) Methoxyethyldithiocarbamate Complexes

Contact Info

Product

Resources

About